Multiple sclerosis (MS) is a chronic disease with an underlying pathology characterized by inflammation-driven neuronal loss, axonal injury, and demyelination. Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase and member of the TEC family of kinases, is involved in the regulation, migration, and functional activation of B cells and myeloid cells in the periphery and the central nervous system (CNS), cell types which are deemed central to the pathology contributing to disease progression in MS patients. Herein, we describe the discovery of BIIB129 (25), a structurally distinct and brain-penetrant targeted covalent inhibitor (TCI) of BTK with an unprecedented binding mode responsible for its high kinome selectivity. BIIB129 (25) demonstrated efficacy in disease-relevant preclinical in vivo models of B cell proliferation in the CNS, exhibits a favorable safety profile suitable for clinical development as an immunomodulating therapy for MS, and has a low projected total human daily dose.
23 May 2016 in European Journal of Organic Chemistry
Relying on our previous achievements toward the a total synthesis of bielschowskysin, 1-5 we herein report additional efforts to close the bridged tetradecane carbocyclic core of this marine diterpene. The key step of this strategy is an intramolecular alkylation between a cis-substituted vinyl halide and a lactone that were accessed by a diastereoselective propargylation/hydrogenation sequence and palladium-catalyzed carbonylation, respectively.
17 March 2025 in Journal of the American Society for Mass Spectrometry